Turning Point Brands (NYSE: TPB) saw its stock surge 5.36% in pre-market trading on Wednesday following the release of its impressive second-quarter 2025 financial results. The company, known for manufacturing and distributing branded consumer products, reported earnings that significantly exceeded analyst expectations.

For Q2 2025, Turning Point reported adjusted earnings per share of $0.98, surpassing the analyst consensus estimate of $0.81 by 20.25%. This represents a 10.11% increase from the $0.89 per share reported in the same period last year. The company's quarterly sales also beat expectations, coming in at $116.63 million, 10.24% above the analyst consensus estimate of $105.80 million and marking a 7.48% year-over-year increase.

Notably, Turning Point's Modern Oral segment experienced substantial growth, with net sales skyrocketing by 651% to $30.1 million, now accounting for 26% of total net sales. This impressive performance, coupled with the company's decision to raise its full-year 2025 guidance, appears to have fueled investor optimism. Turning Point increased its Adjusted EBITDA guidance to a range of $110.0 - $114.0 million, up from the previous $108.0 - $113.0 million, and raised its full-year consolidated Modern Oral sales guidance to $100.0 - $110.0 million from the earlier estimate of $80.0 - $95.0 million. These strong results and positive outlook suggest that Turning Point Brands is well-positioned for continued growth in the coming quarters.